Marc Laskar
French Institute of Health and Medical Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marc Laskar.
International Journal of Cardiology | 2015
Julien Magne; Dania Mohty; Cyrille Boulogne; Mathieu Deltreuil; Claude Cassat; Najmeddine Echahidi; Marc Laskar; Philippe Lacroix; Patrice Virot; Victor Aboyans
INTRODUCTIONnGlobal left ventricular (LV) afterload as assessed by valvulo-arterial impedance (Zva), may be an independent predictor of mortality in patients with severe aortic stenosis (AS) and preserved LV ejection fraction (LVEF). However, its quantification using echocardiography may be subject to error measurement. We aimed to determine the prevalence and impact on long-term survival of high Zva, purposely measured by cardiac catheterization.nnnMETHODS AND RESULTSn676 patients with preserved LVEF and severe AS without other valvular heart diseases underwent cardiac catheterization. Zva was derived from catheterization and calculated as follows: mean aortic gradient+systolic blood pressure/indexed LV stroke volume. Zva was considered high when >5mmHg/mL/m(2) based on previous studies. Overall, high Zva was found in 42% of all AS patients. Four-year survival and 8-year survival were significantly reduced in patients with high Zva (74±3% and 57±4%) as compared to those with low Zva (85±2% and 74±3%; p=0.002). After adjustment for all other risk factors, Zva was independently associated with reduced long-term survival (hazard ratio [HR]=1.47 95% CI: 1.04-2.09; p=0.029). Of interest, high Zva remained associated with reduced survival as compared to low Zva, in patients with normal LV stroke volume, but was no longer significant in low flow patients (p=0.98).nnnCONCLUSIONnHigh Zva, estimated invasively in our study, is frequent in patients with severe AS, and appears as a robust and independent predictor of survival. Zva should be used as an additional parameter for risk stratification of severe AS, more particularly in patients with normal flow.
Archive | 2016
Francis Pesteil; Hassan Houmaida; Clarisse Éveno-Saunier; Marc Laskar; Philippe Lacroix
Maladies Artérielles | 2016
Francis Pesteil; Hassan Houmaida; Clarisse Éveno-Saunier; Marc Laskar; Philippe Lacroix
/data/revues/18786480/v7i1/S187864801571637X/ | 2015
Fatima Ezzahra Boubadara; Julien Magne; Patrice Virot; Marc Laskar; Dania Mohty; Victor Aboyans
2ème Congrès International de Cardiologie | 2014
Philippe Lacroix; Ileana Desormais; Marc Laskar; Victor Aboyans; Pierre-Marie Preux
/data/revues/00029149/unassign/S0002914914014374/ | 2014
Victor Aboyans; Benedicte Tanguy; Ileana Desormais; Vincent Bonnet; Michel Chonchol; Marc Laskar; Dania Mohty; Philippe Lacroix
Archive | 2010
Alexandre Le Guyader; F. Bertin; Marc Laskar; Elisabeth Cornu
European Society of Cardiology congress | 2010
Philippe Lacroix; Victor Aboyans; P. Combres; J. Hammel; Philippe Stierer; Nathalie Nathan-Denizot; Marc Laskar
Archive | 2009
Lucas Sanders; Mark A.J. Newman; Charles Gairdner; Victor Aboyans; Philippe Lacroix; Marc Laskar; Martin Luther
European Society of Cardiology congress | 2008
Victor Aboyans; Ileana Desormais; Philippe Lacroix; K. Rhaiem; Johanna Salazar; Michael H. Criqui; Marc Laskar